Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)
Introduction. The pandemic of the new coronavirus infection COVID-19 (Coronavirus Disease 2019) was caused by a single-stranded RNA virus SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2). Molnupiravir is an antiviral drug with activity against RNA viruses including SARS-CoV-2. Mo...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2024-03-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Assuntos: | |
| Acceso en liña: | https://www.pharmjournal.ru/jour/article/view/1754 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|